Warberg Asset Management’s Cellyan Biotechnology HKPD Stock Holding History

Warberg Asset Management’s Portfolio HKPD Stock Details HKPD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,000	Closed	-$16.2K	–	232
2025 Q1	$16.2K	Buy	+15,000	New	+$26.5K	﹤0.01%	146

Other funds holding HKPD

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VNA

Valley National Advisers Bethlehem, Pennsylvania $900M AUM 31.19% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Warberg Asset Management's HKPD Position: Q2 2025 in Review

Warberg Asset Management sold out of Cellyan Biotechnology (HKPD) in Q2 2025, closing a stake of 15,000 shares — an estimated $16.2K sold.

Warberg Asset Management first reported a position in HKPD in Q1 2025 and held it in 1 quarter. The position peaked at $16.2K in Q1 2025. 6 funds tracked by Wall St. Rank hold HKPD as of Q2 2025.

Warberg Asset Management reported no remaining Cellyan Biotechnology position as of Q2 2025 after selling out during the quarter.
Warberg Asset Management sold 15,000 Cellyan Biotechnology shares in Q2 2025, an estimated $16.2K.
Warberg Asset Management first reported a position in Cellyan Biotechnology in Q1 2025 and held it in 1 quarter.
Warberg Asset Management's Cellyan Biotechnology position peaked at $16.2K in Q1 2025.
6 funds tracked by Wall St. Rank held Cellyan Biotechnology as of Q2 2025.

Based on Warberg Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.